Literature DB >> 6775776

Tumoral calcinosis: evidence for concurrent defects in renal tubular phosphorus transport and in 1 alpha,25-dihydroxycholecalciferol synthesis.

J E Zerwekh, L A Sanders, J Townsend, C Y Pak.   

Abstract

A 50-year-old Latin American man with tumoral calcinosis presented with hyperphosphatemia (6.62 +/- 1.04 SD mg/dl), elevated renal threshold phosphorus concentration (TmP) (7.3 mg/GFR), and 1,25-dihydroxyvitamin D [1,25-(OH)2D] (69 pg/ml) hypercalciuria (239 mg/day), and a high fractional intestinal calcium (Ca) absorption (0.74). Sodium cellulose phosphate therapy (20 g/day) lowered urinary Ca, and partially reduced serum phosphorus (P) and TmP to 5.91 +/- 0.63 mg/dl and 6.2 mg/GFR, respectively. Serum 1,25-(OH)2D remained elevated at 58-64 pg/ml. Amphojel therapy (4 oz/day) decreased urinary P to 23 +/- 21 mg/day and lowered serum P to 5.75 +/- 0.36 mg/dl (P < 0.05). TmP increased to a value of 8.0 mg/GFR while serum 1,25-(OH)2D continued to remain elevated at 53 pg/ml. This case illustrates the probable operation of dual abnormalities in tumoral calcinosis represented by augmented renal conservation of P and an elevation in the circulating concentration of 1,25-(OH)2D.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6775776     DOI: 10.1007/bf02408515

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  25 in total

1.  A sensitive, precise, and convenient method for determination of 1,25-dihydroxyvitamin D in human plasma.

Authors:  J A Eisman; A J Hamstra; B E Kream; H F DeLuca
Journal:  Arch Biochem Biophys       Date:  1976-09       Impact factor: 4.013

2.  Evaluation of calcium urolithiasis in ambulatory patients: comparison of results with those of inpatient evaluation.

Authors:  C Y Pak; C Fetner; J Townsend; L Brinkley; C Northcutt; D E Barilla; M Kadesky; P Peters
Journal:  Am J Med       Date:  1978-06       Impact factor: 4.965

Review 3.  The kidney as an endocrine organ for the production of 1,25-dihydroxyvitamin D 3 , a calcium-mobilizing hormone.

Authors:  H F DeLuca
Journal:  N Engl J Med       Date:  1973-08-16       Impact factor: 91.245

4.  Filter assay for 1alpha, 25-dihydroxyvitamin D3. Utilization of the hormone's target tissue chromatin receptor.

Authors:  P F Brumbaugh; D H Haussler; K M Bursac; M R Haussler
Journal:  Biochemistry       Date:  1974-09-24       Impact factor: 3.162

5.  Hyperphosphatemia and tumoral calcinosis.

Authors:  J F Wilber; E Slatopolsky
Journal:  Ann Intern Med       Date:  1968-05       Impact factor: 25.391

6.  Effect of parathyroidectomy on serum 1 alpha,25-dihydroxyvitamin D and intestinal calcium absorption in primary hyperparathyroidism.

Authors:  H G Bone; J E Zerwekh; M R Haussler; C Y Pak
Journal:  J Clin Endocrinol Metab       Date:  1979-05       Impact factor: 5.958

7.  Tumoral calcinosis: a manifestation of extreme metastatic calcification occurring with 1, alpha-hydroxycholecalciferol therapy.

Authors:  G S Walker; A M Davison; M Peacock; M S McLachlan
Journal:  Postgrad Med J       Date:  1977-09       Impact factor: 2.401

8.  Tumoral calcinosis. A clinical and pathological study of eleven unreported cases in Turkey.

Authors:  U Hacihanefioğlu
Journal:  J Bone Joint Surg Am       Date:  1978-12       Impact factor: 5.284

9.  An unique form of osteomalacia associated with end organ refractoriness to 1,25-dihydroxyvitamin D and apparent defective synthesis of 25-hydroxyvitamin D.

Authors:  J E Zerwekh; K Glass; J Jowsey; C Y Pak
Journal:  J Clin Endocrinol Metab       Date:  1979-08       Impact factor: 5.958

10.  Metabolic effects of diphosphonate in primary hyperparathyroidism.

Authors:  R A Kaplan; W B Geho; C Poindexter; M Haussler; G W Dietz; C Y Pak
Journal:  J Clin Pharmacol       Date:  1977-07       Impact factor: 3.126

View more
  9 in total

1.  [Teutschländer disease. A rare benign differential diagnosis of proliferative space-occupying lesions in the periarticular soft tissue].

Authors:  T Mumme; H Griefingholt; B Schmidt-Rohlfing; R Müller-Rath; A Kochs
Journal:  Orthopade       Date:  2004-07       Impact factor: 1.087

2.  Tumoral calcinosis revisited--common and uncommon features. Report of ten cases and review.

Authors:  A Metzker; B Eisenstein; J Oren; R Samuel
Journal:  Eur J Pediatr       Date:  1988-02       Impact factor: 3.183

3.  Effects of the acute subcutaneous administration of synthetic salmon calcitonin in tumoral calcinosis.

Authors:  R Candrina; B Cerudelli; V Braga; A Salvi
Journal:  J Endocrinol Invest       Date:  1989-01       Impact factor: 4.256

4.  Vitamin D metabolism in tumoral calcinosis.

Authors:  R Steinherz
Journal:  Eur J Pediatr       Date:  1989-02       Impact factor: 3.183

5.  Tumoral calcinosis with hyperphosphatemia.

Authors:  S Mahadevan; B Adhisivam; Chandra N Kumar
Journal:  Indian J Pediatr       Date:  2005-10       Impact factor: 1.967

6.  Hyperphosphatemic tumoral calcinosis in a young dog with renal failure.

Authors:  A L Croom; D M Houston
Journal:  Can Vet J       Date:  1994-07       Impact factor: 1.008

7.  Tumoral calcinosis-like lesion of the proximal linea aspera.

Authors:  L L Seeger; D L Butler; J J Eckardt; L Layfield; J S Adams
Journal:  Skeletal Radiol       Date:  1990       Impact factor: 2.199

Review 8.  Tumoral calcinosis: case report and review.

Authors:  A F Bishop; J M Destouet; W A Murphy; L A Gilula
Journal:  Skeletal Radiol       Date:  1982       Impact factor: 2.199

9.  Tumoral calcinosis: a case report.

Authors:  J Prasad; S Malua; D K Sinha; F Hassan; R Tekriwal
Journal:  Indian J Surg       Date:  2008-01-28       Impact factor: 0.656

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.